Israel targets Teva over MS drug royalties
12-05-2022
EU should buy patent rights for COVID-19 tests, says Greece
07-04-2020
Costa Rica asks WHO to create voluntary COVID-19 IP pool
26-03-2020
Piotr Swat / Shutterstock.com
Israel has approved generic versions of an HIV antiviral owned by AbbVie for use in treating coronavirus, despite the company still holding patent protection and doubts over its effectiveness.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
COVID-19, AbbVie, HIV, coronavirus, antiviral, Israel, lopinavir-ritonavir, Kaletra, New England Journal of Medicine
